Revising Oral Pharmacokinetics, Bioavailability and Bioequivalence Based on the Finite Absorption Time Concept [E-Book]

Part I: Oral Pharmacokinetics -- Chapter 1. From Bateman (1908) To Dost (1953) -- Chapter 2. The Unphysical Hypothesis Of Infinite Absorption Time -- Chapter 3. The Finite Absorption Time (Fat) Concept -- Chapter 4. The Rise Of Physiologically Based Finite Time Pharmacokinetic (Pbftpk) Models -- Part II: Bioavailability-Bioequivalence -- Chapter 5. History Of The Bioavailability-Bioequivalence Concepts -- Chapter 6. Therapeutic Equivalence Based On Bioequivalence Studies -- Chapter 7. Bioavailability Under The Prism Of Finite Absorption Time -- Chapter 8. Bioequivalence Under The Prism Of Finite Absorption Time.

This book casts new light on the field of oral drug absorption. It outlines both the concept of the past and the novel concept of Finite Absorption Time (FAT). In addition, the authors explore the correlated need for re-definition of bioavailability, bioequivalence providing a plethora of experimental data. Accordingly, this book is intended for academics/students or scientists working in pharmaceutical industries, regulatory agencies, and contract research organizations. It can be used for teaching purposes in under- and post-graduate courses dealing with biopharmaceutics, pharmacokinetics and biomedical engineering. This excellent text serves as a historical review of drug absorption kinetics and its application to bioavailability and bioequivalence. However, its main thrust is the application of the authors' innovative new approaches to modifying these processes utilizing concepts of finite absorption time (FAT) and physiologically based finite time pharmacokinetic (PBFTPK) models. The work described in detail is based on the innovative experimental studies, many in depth examples and simulations, and the authors' outstanding theoretical contributions to our understanding of drug gastrointestinal absorption, and drug pharmacokinetics. I found the book to be an enjoyable and enlightening read. Professor Leslie Benet, Department of Bioengineering & Therapeutic Sciences, Schools of Pharmacy & Medicine, University of California, San Francisco, USA.